Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RMS2
MCID: RHB024
MIFTS: 67

Rhabdomyosarcoma 2 (RMS2)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Rhabdomyosarcoma 2

About this section

MalaCards integrated aliases for Rhabdomyosarcoma 2:

Name: Rhabdomyosarcoma 2 57 73
Alveolar Rhabdomyosarcoma 12 20 58 29 6 15 17 71
Rhabdomyosarcoma, Alveolar 57 74 44
Rhabdomyosarcoma Alveolar 20 73 54
Alveolar Childhood Rhabdomyosarcoma 12 71
Rhabdomyosarcoma 2, Alveolar 57 13
Rms2 57 73
Rmsa 57 73
Rhabdomyosarcoma, Alveolar; Rmsa 57
Rhabdomyosarcoma, Type 2 39
Arms 20

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation


HPO:

31
rhabdomyosarcoma 2:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Neuronal diseases Muscle diseases Bone diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4051
OMIM® 57 268220
MeSH 44 D018232
NCIt 50 C3749 C7958
SNOMED-CT 67 404053004
MESH via Orphanet 45 D018232
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0206655
Orphanet 58 ORPHA99756
MedGen 41 C0206655
SNOMED-CT via HPO 68 124975008 63449009
UMLS 71 C0206655 C0279613
Sources

Summaries for Rhabdomyosarcoma 2

About this section
UniProtKB/Swiss-Prot : 73 Rhabdomyosarcoma 2: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

MalaCards based summary : Rhabdomyosarcoma 2, also known as alveolar rhabdomyosarcoma, is related to spindle cell sarcoma and sarcoma. An important gene associated with Rhabdomyosarcoma 2 is PAX7 (Paired Box 7), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Fluvoxamine and Tigecycline have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and liver, and related phenotypes are alveolar rhabdomyosarcoma and cellular

Wikipedia : 74 Alveolar rhabdomyosarcoma (ARMS) is a subtype of the rhabdomyosarcoma soft tissue cancer family whose... more...

More information from OMIM: 268220
Sources

Related Diseases for Rhabdomyosarcoma 2

About this section

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 spindle cell sarcoma 31.2 MYOG MDM2 DES
2 sarcoma 30.8 WT1 RB1 MYOG MDM2 CDK4 ALK
3 prostate rhabdomyosarcoma 30.7 MYOG MYOD1
4 embryonal rhabdomyosarcoma 30.6 PAX7 PAX3 MYOG MYOD1 MYCN MDM2
5 skeletal muscle neoplasm 30.6 RHD MYOG MYOD1 MB
6 osteogenic sarcoma 30.6 WT1 RB1 MDM2 IGF1R CDK4
7 beckwith-wiedemann syndrome 30.5 WT1 TH PAX7 MYOD1 IGF1R
8 breast rhabdomyosarcoma 30.5 PAX7 PAX3 MYOG MYOD1 MB FOXO1
9 desmoplastic small round cell tumor 30.4 WT1 PAX3 MYOG MYOD1 ENO2 DES
10 alveolar soft part sarcoma 30.4 MYOG MYOD1 MB ENO2 DES
11 pleomorphic rhabdomyosarcoma 30.4 PAX7 PAX3 MYOG MYOD1 MB FOXO1
12 orbit rhabdomyosarcoma 30.4 PAX7 PAX3 MYOG MYCN MB FOXO1
13 connective tissue benign neoplasm 30.4 MDM2 ENO2 CDK4
14 fibrous histiocytoma 30.4 ENO2 DES ALK
15 familial retinoblastoma 30.3 RB1 MDM2 CDK4
16 mesenchymal chondrosarcoma 30.3 MYOG MYOD1 ENO2 DES
17 malignant fibrous histiocytoma 30.3 MYOG MYOD1 MDM2 MB DES CDK4
18 neuroblastoma 30.2 TH MYCN MDM2 IGF1R ENO2 DIABLO
19 li-fraumeni syndrome 30.2 RB1 MYCN MDM2 CDK4
20 botryoid rhabdomyosarcoma 30.2 PAX3 MYOG MYOD1 MB DES
21 gliosarcoma 30.2 RB1 MDM2 ENO2 CDK4
22 malignant mesenchymoma 30.2 MYOG MYOD1 MDM2 MB DES
23 muscular dystrophy, duchenne type 30.2 PAX7 MYOG MYOD1 MB DES
24 retinoblastoma 30.1 RB1 MYOG MYOD1 MYCN MDM2 ENO2
25 liposarcoma 30.1 RB1 MYOG MDM2 MB IGF1R DES
26 wilms tumor 1 29.9 WT1 MYOG MYOD1 MYCN IGF1R ENO2
27 leukemia, acute myeloid 29.9 WT1 MYCN MDM2 FOXO1 DIABLO CDK4
28 sarcoma, synovial 29.8 WT1 PAX3 MYOG MYCN MDM2 IGF1R
29 ewing sarcoma 29.8 WT1 PAX7 PAX3 MYOG MYCN MDM2
30 endometrial cancer 29.8 WT1 RB1 MDM2 IGF1R FOXO1 CDK4
31 leiomyosarcoma 29.7 WT1 RB1 MYOG MDM2 MB ENO2
32 muscle cancer 29.5 RMST RHD PAX7 PAX3 MYOG MYOD1
33 skeletal muscle cancer 29.5 WT1 RMST RHD PAX7 PAX3 MYOG
34 rhabdomyosarcoma 28.7 WT1 RMST RB1 PAX7 PAX3 MYOG
35 orbit alveolar rhabdomyosarcoma 11.3
36 mixed type rhabdomyosarcoma 11.1
37 soft tissue sarcoma 10.7
38 central nervous system rhabdomyosarcoma 10.5 PAX3 FOXO1
39 myoblastoma 10.5 MYOG ENO2
40 ring chromosome 7 10.5 MDM2 CDK4
41 spermatic cord cancer 10.5 WT1 MYOD1
42 mediastinum liposarcoma 10.5 MDM2 CDK4
43 gastric liposarcoma 10.5 MDM2 CDK4
44 heart lymphoma 10.5 MYOG ALK
45 infiltrating lipoma 10.5 MDM2 CDK4
46 spindle cell liposarcoma 10.5 MDM2 CDK4
47 pediatric liposarcoma 10.5 MDM2 CDK4
48 adult fibrosarcoma 10.5 MYOG MYOD1
49 epididymal neoplasm 10.5 WT1 MYOD1
50 giant cell myocarditis 10.5 MB DES

Graphical network of the top 20 diseases related to Rhabdomyosarcoma 2:



Diseases related to Rhabdomyosarcoma 2
Sources

Symptoms & Phenotypes for Rhabdomyosarcoma 2

About this section

Human phenotypes related to Rhabdomyosarcoma 2:

31
# Description HPO Frequency HPO Source Accession
1 alveolar rhabdomyosarcoma 31 HP:0006779

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
alveolar rhabdomyosarcoma

Clinical features from OMIM®:

268220 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Rhabdomyosarcoma 2:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 CDK4 DES DIABLO ENO2 FOXO1 IGF1R
2 behavior/neurological MP:0005386 10.44 ALK CDK4 DES DIABLO ENO2 FOXO1
3 growth/size/body region MP:0005378 10.43 ALK CDK4 DIABLO ENO2 FOXO1 IGF1R
4 homeostasis/metabolism MP:0005376 10.41 ALK CDK4 DES FOXO1 IGF1R MB
5 cardiovascular system MP:0005385 10.4 CDK4 DES FOXO1 IGF1R MB MDM2
6 mortality/aging MP:0010768 10.33 ALK CDK4 DES FOXO1 IGF1R MB
7 embryo MP:0005380 10.29 CDK4 FOXO1 IGF1R MB MDM2 MYCN
8 muscle MP:0005369 10.25 CDK4 DES FOXO1 IGF1R MB MDM2
9 endocrine/exocrine gland MP:0005379 10.24 ALK CDK4 FOXO1 IGF1R MDM2 PAX3
10 craniofacial MP:0005382 10.22 CDK4 ENO2 FOXO1 IGF1R MDM2 MYCN
11 integument MP:0010771 10.19 ALK CDK4 FOXO1 IGF1R MDM2 MYOG
12 digestive/alimentary MP:0005381 10.16 CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
13 neoplasm MP:0002006 10.14 ALK CDK4 FOXO1 IGF1R MDM2 MYOD1
14 liver/biliary system MP:0005370 10.13 CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
15 nervous system MP:0003631 10.11 ALK CDK4 ENO2 FOXO1 IGF1R MDM2
16 normal MP:0002873 10.07 ALK CDK4 DIABLO FOXO1 MDM2 MYCN
17 no phenotypic analysis MP:0003012 10.02 FOXO1 MDM2 MYCN MYOD1 MYOG PAX3
18 respiratory system MP:0005388 9.73 ALK ENO2 IGF1R MB MYCN MYOD1
19 pigmentation MP:0001186 9.55 ALK CDK4 MDM2 PAX3 RB1
20 skeleton MP:0005390 9.36 ALK CDK4 FOXO1 IGF1R MDM2 MYCN
Sources

Drugs & Therapeutics for Rhabdomyosarcoma 2

About this section

Drugs for Rhabdomyosarcoma 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1616)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
2
Tigecycline Approved Phase 4 220620-09-7 5282044
3
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
4
Zoledronic Acid Approved Phase 4 118072-93-8 68740
5
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
6
Glycerol Approved, Investigational Phase 4 56-81-5 753
7
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
8
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
9
Cyclopentolate Approved Phase 4 512-15-2 2905
10
Terbutaline Approved Phase 4 23031-25-6 5403
11
Trimebutine Approved Phase 4 39133-31-8
12
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
13
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
14
Opium Approved, Illicit Phase 4 8008-60-4
15
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
16 Tangerine Approved Phase 4
17
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
18
Lorazepam Approved Phase 4 846-49-1 3958
19
Topiramate Approved Phase 4 97240-79-4 5284627
20
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
21
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
22
Phenylephrine Approved Phase 4 59-42-7 6041
23
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
24
Teicoplanin Approved, Investigational Phase 4 61036-62-2
25
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
28
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
29
Orphenadrine Approved Phase 4 83-98-7 4601
30
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
31
Tranexamic Acid Approved Phase 4 1197-18-8 5526
32
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
33
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
34
Glimepiride Approved Phase 4 93479-97-1 3476
35
Cetirizine Approved Phase 4 83881-51-0 2678
36
Azelastine Approved Phase 4 58581-89-8 2267
37
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
38
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
39
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
40
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
41
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
42
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
43
alemtuzumab Approved, Investigational Phase 4 216503-57-0
44
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
45
Nevirapine Approved Phase 4 129618-40-2 4463
46
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
47
Ranibizumab Approved Phase 4 347396-82-1 459903
48
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
49
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
50
Prilocaine Approved Phase 4 721-50-6 4906

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
2 Concentration and Antibiotic Activity in Antibiotic Lock Solutions Unknown status NCT01592032 Phase 4 Vancomycin antimicrobial-lock solution;Teicoplanin antimicrobial-lock solution;Linezolid antimicrobial-lock solution;Daptomycin antimicrobial-lock solution;Tigecycline antimicrobial-lock solution
3 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children Unknown status NCT01944189 Phase 4
4 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
5 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
6 Multicenter, Prospective, Randomized Study Investigating the Efficacy and Safety of a Reduced Immunosuppressive Therapy With Tacrolimus Once Daily in Comparison to Standard Triple Immunosuppression in Senior Renal Transplant Recipients Unknown status NCT02453867 Phase 4 Tacrolimus;mycophenolate;Steroids
7 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
8 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
9 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
10 Effects of Various Volume of Local Anaesthetic Use for Ultrasound Guided Supraclavicular Brachial Plexus Block on Successful Blockade and Diaphragmatic Motility. Unknown status NCT03476694 Phase 4
11 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
12 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
13 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
14 Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial Unknown status NCT02655562 Phase 4 Montelukast
15 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
16 Assessment of Implantation Potential of Embryos Cultured by Time-lapse Technology (Embryoscope) Before Transfer in In-vitro Fertilization (IVF) / Intracytoplasmic Sperm Injection (ICSI) Cycles: A Randomized Control Study. Unknown status NCT01760278 Phase 4 recombinant Follicle Stimulating Hormone (rFSH)
17 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
18 Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting Unknown status NCT03450161 Phase 4 Fentanyl dosing schemes
19 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
20 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
21 Long Acting FSH Plus GnRH Antagonist Versus Daily FSH Plus GnRH Antagonist Versus Short Agonist Regimens in Poor Responder Patients Undergoing IVF: a Randomized Study. Unknown status NCT02070198 Phase 4 Long acting FSH and GnRH antagonist;Daily FSH and GnRH antagonist;Triptorelin and recombinant FSH
22 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
23 Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level Unknown status NCT02373163 Phase 4 Hydrochlorothiazide;Amlodipine;Telmisartan
24 Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy Unknown status NCT01662687 Phase 4 Sancuso patch;Kytril inj.+Kytril tab.
25 Effect of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function in Healthy Subjects and Patients With Osteoarthritis Unknown status NCT03781544 Phase 4 Tramadol;Paracetamol;Diclofenac
26 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
27 Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial Unknown status NCT00927550 Phase 4 lithium;usual care
28 Brain Mechanisms For Clinical Placebo in Chronic Pain: A Randomized Clinical Trial of Placebo, Active Treatment, and No Treatment in Chronic Back Pain Unknown status NCT02986334 Phase 4 Naproxen;Omeprazole;Placebo
29 A Comparison Between Flexible Ureteroscopy, Semirigid Ureteroscopy and Extracorporeal Shockwaves Lithotripsy (SWL) in The Management of Proximal Ureteric Stones. A Randomized Controlled Trial Unknown status NCT02469766 Phase 4
30 A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
31 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
32 Radiofrequency Ablation Using Dual Cooled-Wet Electrode for Small Hepatocellular Carcinoma With No-touch Technique: Preliminary Study Unknown status NCT02806076 Phase 4
33 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Unknown status NCT02851303 Phase 4 Morphine;Methadone
34 Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients Unknown status NCT02117986 Phase 4 colistin
35 Photodynamic Therapy for Papulopustular Rosacea Unknown status NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
36 The Analgesic Effects of Morphine Versus Ketorolac in Low Back Pain Unknown status NCT02782286 Phase 4 Ketorolac;Morphine
37 The Analgesic Effects of Morphine Versus Ketorolac in Renal Colic Unknown status NCT02782273 Phase 4 Ketorolac;Morphine
38 Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor) Unknown status NCT01937325 Phase 4 ivacaftor;placebo
39 Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) Unknown status NCT01914367 Phase 4
40 Safety and Efficacy of Fluvastatin in Heart Transplant Recipients Unknown status NCT00421005 Phase 4 fluvastatin
41 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
42 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
43 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
44 The Use of Bronchial Blocker Versus Double Lumen Tube for One-lung Ventilation During Thoracoscope Assisted Mitral Valve Replacement Unknown status NCT02729610 Phase 4
45 Efficacy of Peri-trigonal Onabotulinumtoxin Injections in the Treatment of Refractory Idiopathic Detrusor Overactivity (IDO): A Single-blind, Randomised Controlled Trial Comparing Peri-trigonal Injections vs Injection of the Bladder Body. Unknown status NCT02009540 Phase 4 Botulinum toxin injected to bladder body;Botulinum toxin injected into trigone
46 Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy Unknown status NCT02000297 Phase 4
47 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
48 Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
49 Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial. Unknown status NCT02594631 Phase 4
50 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4

Search NIH Clinical Center for Rhabdomyosarcoma 2

Cochrane evidence based reviews: rhabdomyosarcoma, alveolar

Sources

Genetic Tests for Rhabdomyosarcoma 2

About this section

Genetic tests related to Rhabdomyosarcoma 2:

# Genetic test Affiliating Genes
1 Alveolar Rhabdomyosarcoma (disease) 29 FOXO1 PAX3 PAX7
Sources

Anatomical Context for Rhabdomyosarcoma 2

About this section

MalaCards organs/tissues related to Rhabdomyosarcoma 2:

40
Prostate, Bone, Liver, Skin, Myeloid, T Cells, Breast
Sources

Publications for Rhabdomyosarcoma 2

About this section

Articles related to Rhabdomyosarcoma 2:

(show top 50) (show all 1073)
# Title Authors PMID Year
1
Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. 54 61 57
8643596 1996
2
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. 57 61 54
8275086 1993
3
Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. 57 61 54
8098985 1993
4
Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? 57 61
11556833 2001
5
Localization of the t(2;13) breakpoint of alveolar rhabdomyosarcoma on a physical map of chromosome 2. 61 57
1505949 1992
6
Chromosomal sublocalization of the 2;13 translocation breakpoint in alveolar rhabdomyosarcoma. 57 61
1382566 1992
7
Localization of the rhabdomyosarcoma t(2;13) breakpoint on a physical map of chromosome 13. 61 57
1783402 1991
8
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. 57
12368906 2002
9
Translocation 2;8 in a congenital rhabdomyosarcoma. 57
3342389 1988
10
Chromosomal analysis of sixteen human rhabdomyosarcomas. 57
3338090 1988
11
A specific chromosomal abnormality in rhabdomyosarcoma. 57
3691179 1987
12
The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma. 61 54
19704258 2009
13
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. 54 61
19707204 2009
14
Structural basis for DNA recognition by the human PAX3 homeodomain. 61 54
19199574 2009
15
Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. 61 54
18386058 2008
16
Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts. 61 54
18705836 2008
17
Rhabdomyosarcoma an ubiquitous pediatric tumour. 61 54
18727437 2008
18
Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. 61 54
18414034 2008
19
[Diagnosis of micrometastases of alveolar rhabdomyosarcoma]. 54 61
18540440 2008
20
Comparison of the proximal promoter regions of the PAX3 and PAX7 genes. 54 61
17954266 2007
21
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 61 54
16140913 2005
22
Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. 61 54
15313887 2004
23
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. 61 54
15184910 2004
24
The MYCN oncoprotein as a drug development target. 61 54
12880971 2003
25
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. 54 61
11863357 2002
26
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. 54 61
11735247 2001
27
Regulating the neoplastic phenotype using engineered transcriptional repressors. 54 61
11164187 2001
28
Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. 61 54
10700864 2000
29
A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. 61 54
10616906 1999
30
PAX3 gene structure, alternative splicing and evolution. 54 61
10521655 1999
31
PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. 61 54
10439042 1999
32
The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. 61 54
9858583 1999
33
Normal and rearranged PAX3 expression in human rhabdomyosarcoma. 54 61
9546061 1998
34
Chromosomal translocations involving paired box transcription factors in human cancer. 54 61
9570138 1997
35
The genomic organization and the full coding region of the human PAX7 gene. 54 61
9339373 1997
36
Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines. 54 61
9294613 1997
37
[Pathologic diagnosis on bone and soft tissue tumors by molecular biological methods]. 54 61
9256013 1997
38
Expression of PAX3 in Ewing's sarcoma family of tumors. 54 61
9169092 1997
39
Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. 61 54
8889501 1996
40
Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. 61 54
8875708 1996
41
Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. 61 54
9052994 1996
42
MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). 54 61
8751388 1996
43
Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. 54 61
8634710 1995
44
The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. 54 61
7630639 1995
45
Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. 61 54
7624119 1995
46
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. 61 54
8083365 1994
47
Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. 61 54
8221646 1993
48
Orbital rhabdomyosarcoma. Immunohistochemical studies of seven cases. 54 61
2119961 1990
49
Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. 61
33245207 2021
50
Long non-coding RNA RMST promotes oxygen-glucose deprivation-induced injury in brain microvascular endothelial cells by regulating miR-204-5p/VCAM1 axis. 61
33607153 2021
Sources

Variations for Rhabdomyosarcoma 2

About this section

ClinVar genetic disease variations for Rhabdomyosarcoma 2:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PAX7 NM_001135254.2(PAX7):c.220C>T (p.Arg74Ter) SNV Likely pathogenic 689508 rs1176071790 1:18960931-18960931 1:18634437-18634437
2 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg) SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655
3 PAX3 NM_181458.4(PAX3):c.580G>A (p.Glu194Lys) SNV Uncertain significance 504786 rs148454691 2:223158892-223158892 2:222294173-222294173
4 PAX3 NM_181458.4(PAX3):c.540C>G (p.Ser180Arg) SNV Uncertain significance 504788 rs200679164 2:223158932-223158932 2:222294213-222294213

Cosmic variations for Rhabdomyosarcoma 2:

9 (show top 50) (show all 679)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93183630 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.743G>A p.R248Q 17:7674220-7674220 8
2 COSM112255322 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
3 COSM122271658 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.337G>T p.G113C 17:7674230-7674230 8
4 COSM145017865 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.616G>A p.G206S 17:7674230-7674230 8
5 COSM142605762 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.754A>C p.K252Q 17:7673749-7673749 8
6 COSM144013587 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.700G>A p.G234S 17:7674230-7674230 8
7 COSM122271355 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.305A>G p.Y102C 17:7674262-7674262 8
8 COSM143576669 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.551C>G p.P184R 17:7674863-7674863 8
9 COSM106096066 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
10 COSM145017326 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.407G>A p.R136H 17:7675088-7675088 8
11 COSM144544530 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.494A>G p.E165G 17:7674920-7674920 8
12 COSM144020071 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.695T>C p.M232T 17:7674235-7674235 8
13 COSM112297123 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
14 COSM93183307 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 8
15 COSM144015364 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.604C>T p.R202* 17:7674894-7674894 8
16 COSM143371076 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.616G>A p.G206S 17:7674230-7674230 8
17 COSM142845635 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.961A>T p.K321* 17:7673567-7673567 8
18 COSM87906219 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.728T>C p.M243T 17:7674235-7674235 8
19 COSM93229090 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
20 COSM145024780 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.611T>C p.M204T 17:7674235-7674235 8
21 COSM121884328 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.332T>C p.M111T 17:7674235-7674235 8
22 COSM121878773 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.241C>T p.R81* 17:7674894-7674894 8
23 COSM105622516 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
24 COSM143386796 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.134A>G p.E45G 17:7674920-7674920 8
25 COSM112446896 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.739A>G p.N247D 17:7674224-7674224 8
26 COSM122105750 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.272C>G p.P91R 17:7674863-7674863 8
27 COSM142838784 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
28 COSM143984574 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.394A>C p.K132Q 17:7673749-7673749 8
29 COSM143946062 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.160C>T p.R54* 17:7674894-7674894 8
30 COSM143943565 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.47G>A p.R16H 17:7675088-7675088 8
31 COSM144651337 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.616G>A p.G206S 17:7674230-7674230 8
32 COSM145221104 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.551C>G p.P184R 17:7674863-7674863 8
33 COSM144120969 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.394A>C p.K132Q 17:7673749-7673749 8
34 COSM122781709 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.475A>C p.K159Q 17:7673749-7673749 8
35 COSM111802670 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
36 COSM88149182 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.668C>G p.P223R 17:7674863-7674863 8
37 COSM142570943 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.844A>T p.K282* 17:7673567-7673567 8
38 COSM105620276 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.743G>A p.R248Q 17:7674220-7674220 8
39 COSM142837352 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.743G>A p.R248Q 17:7674220-7674220 8
40 COSM106059837 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.728T>C p.M243T 17:7674235-7674235 8
41 COSM87949760 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
42 COSM143413354 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.754A>C p.K252Q 17:7673749-7673749 8
43 COSM144182541 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.706A>G p.N236D 17:7674224-7674224 8
44 COSM122271749 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.337G>A p.G113S 17:7674230-7674230 8
45 COSM111760544 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
46 COSM111765613 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.728T>C p.M243T 17:7674235-7674235 8
47 COSM143943621 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.224A>G p.Y75C 17:7674262-7674262 8
48 COSM112264430 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.961A>T p.K321* 17:7673567-7673567 8
49 COSM142771096 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.551C>G p.P184R 17:7674863-7674863 8
50 COSM121876092 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.337G>T p.G113C 17:7674230-7674230 8

Copy number variations for Rhabdomyosarcoma 2 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25460 1 18957499 19075360 Amplification PAX7 Alveolar rhabdomyosarcoma
2 76221 13 28900000 50900000 Amplification FOXO1 Alveolar rhabdomyosarcoma
3 141698 2 215300000 221500000 Amplification PAX3 Alveolar rhabdomyosarcoma
Sources

Expression for Rhabdomyosarcoma 2

About this section
Search GEO for disease gene expression data for Rhabdomyosarcoma 2.
Sources

Pathways for Rhabdomyosarcoma 2

About this section

Pathways related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.7 RB1 MDM2 IGF1R FOXO1 CDK4
2
Pathways in cancer 36
12.57 RB1 MDM2 IGF1R FOXO1 CDK4 ALK
3
Glioma 36
Show member pathways
 12.4 RB1 MDM2 IGF1R FOXO1 CDK4 ALK
4
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 11.99 RB1 MDM2 IGF1R FOXO1 CDK4
5
Cellular senescence (KEGG) 36
11.95 RB1 MDM2 FOXO1 CDK4
6
Integrated Breast Cancer Pathway 1
11.92 RB1 MDM2 FOXO1 CDK4
7
Senescence and Autophagy in Cancer 1
11.78 RB1 MDM2 IGF1R
8
Androgen receptor signaling pathway 1
11.68 RB1 MDM2 FOXO1
9
Retinoblastoma (RB) in Cancer 1
11.66 RB1 MDM2 CDK4
10
Glioblastoma Multiforme 63
11.6 RB1 MDM2 IGF1R FOXO1 CDK4
11
Regulation of nuclear SMAD2/3 signaling 1
11.59 MYOD1 FOXO1 CDK4
12
Bladder cancer 36 1
11.55 RB1 MDM2 CDK4
13
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.5 RB1 IGF1R CDK4
14
Transcriptional misregulation in cancer 36
11.45 WT1 PAX7 PAX3 MYCN MDM2 IGF1R
15
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.33 PAX7 PAX3 MYOG MYOD1 DES
16
Integrated Cancer Pathway 1
11.32 RB1 MDM2 CDK4
17
Regulation of retinoblastoma protein 1
11.31 RB1 PAX3 MYOD1 MDM2
18
ID signaling pathway 1
10.77 RB1 MYOD1
Sources

GO Terms for Rhabdomyosarcoma 2

About this section

Cellular components related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.28 WT1 RB1 PAX7 PAX3 MYOG MYOD1
2 transcription factor complex GO:0005667 9.26 RB1 MYOG MYOD1 CDK4

Biological processes related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.03 WT1 RB1 PAX7 PAX3 MYOG MYOD1
2 regulation of transcription by RNA polymerase II GO:0006357 9.97 WT1 RB1 PAX7 PAX3 MYOG MYOD1
3 negative regulation of apoptotic process GO:0043066 9.95 WT1 PAX7 MDM2 IGF1R FOXO1
4 positive regulation of transcription, DNA-templated GO:0045893 9.95 WT1 PAX3 MYOG MYOD1 MYCN FOXO1
5 cellular response to growth factor stimulus GO:0071363 9.67 TH MYOG MDM2
6 skeletal muscle cell differentiation GO:0035914 9.58 RB1 MYOG MYOD1
7 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 WT1 RB1 PAX3 MYOG MYOD1 MYCN
8 myotube differentiation GO:0014902 9.54 MYOG MYOD1
9 cellular response to alkaloid GO:0071312 9.52 TH MDM2
10 positive regulation of skeletal muscle fiber development GO:0048743 9.51 MYOG MYOD1
11 muscle cell fate commitment GO:0042693 9.46 MYOG MYOD1
12 muscle organ development GO:0007517 9.46 PAX7 PAX3 MYOG MYOD1
13 positive regulation of muscle cell differentiation GO:0051149 9.43 MYOG MYOD1 MDM2
14 response to ether GO:0045472 9.37 TH MDM2
15 myoblast differentiation GO:0045445 8.8 RB1 MYOG MYOD1

Molecular functions related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.87 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
2 sequence-specific double-stranded DNA binding GO:1990837 9.77 PAX7 PAX3 MYOG MYOD1 MYCN
3 ubiquitin protein ligase binding GO:0031625 9.71 RB1 MYOD1 MDM2 FOXO1
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.7 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
5 sequence-specific DNA binding GO:0043565 9.65 WT1 PAX3 MYOG MYOD1 FOXO1
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.43 WT1 MYOG MYOD1 MYCN MDM2 FOXO1
7 DNA-binding transcription factor activity GO:0003700 9.17 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
Sources

Sources for Rhabdomyosarcoma 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....